A statement from Orange Juice Communications, the organisers of Insulin Safety Week:
We have received funding by means of sponsorship, including from pharmaceutical and medical technology companies, to support the delivery of our campaign. Insulin Safety Week 2026 has been funded by Roche Diagnostics, MiniMed, Sanofi and Ascensia which have had no input into the campaign’s arrangements or content.
A specially developed prototype of GNL Grace, an evidence-graded knowledge educator for people living with type 1 diabetes and the healthcare professionals who care for them, will launch during Insulin Safety Week (ISW) 2026.
GNL Grace is not a general-purpose chatbot. She is an agentic retrieval system built on a structured, graded and human-curated knowledge base, with every answer traceable to a source and every source carrying an explicit evidence grade.
GNL Grace is built on four layers. The first is clinical guidelines, with ISPAD 2024 and ADA 2026 loaded in full.
The second is the GNL evidence wiki, a set of 51 concept pages covering every core type 1 diabetes topic, each carrying an explicit evidence grade.
The third is real-world validation, drawn from 33 population analyses covering more than 10,000 people with type 1 diabetes and over 1.5 million patient-days.
The fourth is the safety framework, with five safety rails hard-coded into the system and tested against a 77-case adversarial suite, which GNL Grace passed with zero genuine failures.
In total, GNL Grace’s knowledge base contains 860 graded evidence items and 349 source summaries, alongside the RESILIENT framework, NPSA/NRLS incident data, inpatient audit findings and the healthcare professional competency model, all carefully graded and structured for reliability.
For the first time, sites participating in this year’s ISW will gain access to a dedicated ISW prototype of GNL Grace, which will replace the traditional static resource pack email with a more dynamic, personalised experience.
The system will match five to eight tailored resources to each healthcare professional’s specific context, prioritising visual content where available. The result is a personalised email featuring selected resources, alongside a clear rationale for each recommendation.
GNL is an independent, evidence-led diabetes education platform that translates complex scientific information into clear, practical guidance for people living with type 1 diabetes.
Founded by John Pemberton, a Registered Dietitian and Diabetes Specialist at Birmingham Women’s and Children’s NHS Foundation Trust, GNL is designed to support clinical decision making, not replace professional judgement.
GNL Grace has been built in partnership with Phillip Hayes, GNL’s Technical Director, whose work on the retrieval architecture underpins how GNL Grace surfaces graded evidence rather than generating it.
John said: “Clinicians do not need another chatbot. They need a knowledge partner that shows where an answer comes from and how strong the evidence behind it is.
“Grace was built for that. Every answer is traceable to a graded source, and where the real-world data contradicts received wisdom we report the contradiction rather than hide it.”
Phillip Hayes added: “The architecture behind Grace is deliberately narrow. She retrieves from a curated, graded knowledge base and she has to show her working.
“That constraint is the point. It is what makes her safe to put in front of a busy clinical team during a week where the focus is insulin safety.”
For more information about GNL, click here.
The central aim of ISW is to raise awareness of insulin safety across healthcare settings. This year’s campaign will also explore how rapid technological advancements are reshaping diabetes care.
From smart insulin pens and app-connected insulin pumps to continuous glucose monitoring (CGM) and hybrid closed-loop (HCL) systems, innovations are transforming how insulin is prescribed, delivered and managed, reducing the daily burden on people living with diabetes and improving outcomes.
Emily Mayhew, Event Manager, said: “ISW has always been about improving awareness and reducing risk, but this year we are once again showcasing how innovation can actively support safer care.
“Tools like GNL Grace have the potential to put high-quality, evidence-based guidance directly into the hands of healthcare professionals when they need it most, helping them make informed decisions with confidence.”
Healthcare professionals from the UK and Northern Ireland can register to take part here.
For more information about Insulin Safety Week 2026 visit www.insulinsafetyweek.com.
